LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study

Qing Zhou(Hunan University of Traditional Chinese Medicine), Yi‐Long Wu(Guangdong General Hospital), Liang Sun(Nanchang University), Da Huang(Wuhan Union Hospital), Yanping Hu(Chinese People's Liberation Army), Megan Zhao(Johns Hopkins University), Yaqi Shen, Meili Sun(Jinan Central Hospital), Jingjing Huang(Second Affiliated Hospital of Nanjing Medical University), Jun Lin(Zhongnan Hospital of Wuhan University), Xue Meng(Shandong First Medical University), R-H. Guo(Jiangsu Province Hospital), Jing Shan, Wu Zhuang(Hunan University), Yan Yu(Harbin Medical University), C. Xu(Guangdong Academy of Medical Sciences), Yueyin Pan(First Affiliated Hospital of Anhui Medical University), Ning Yang(Soochow University), Mengna Huang(Brigham and Women's Hospital)
Annals of Oncology
November 1, 2023
10.1016/j.annonc.2023.10.584
Cited by 10

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k